Esperion Therapeutics, Inc. 0IIM.L Stock
Esperion Therapeutics, Inc. Price Chart
Esperion Therapeutics, Inc. 0IIM.L Financial and Trading Overview
| Esperion Therapeutics, Inc. stock price | 2.15 USD |
| Previous Close | 1.26 USD |
| Open | 0 USD |
| Bid | 0 USD x N/A |
| Ask | 0 USD x N/A |
| Day's Range | 0 - 0 USD |
| 52 Week Range | 0 - 10 USD |
| Volume | 76K USD |
| Avg. Volume | 5.03K USD |
| Market Cap | 451.98K USD |
| Beta (5Y Monthly) | 0.145774 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.24 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0IIM.L Valuation Measures
| Enterprise Value | 475.43M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.0055821436 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 5.872 |
| Enterprise Value/EBITDA | -2.574 |
Trading Information
Esperion Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.145774 |
| 52-Week Change | -75.0086% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10 USD |
| 52 Week Low | 0 USD |
| 50-Day Moving Average | 1.41 USD |
| 200-Day Moving Average | 5.1 USD |
0IIM.L Share Statistics
| Avg. Volume (3 month) | 5.03K USD |
| Avg. Daily Volume (10-Days) | 12.85K USD |
| Shares Outstanding | 26.81M |
| Float | 83.65M |
| Short Ratio | N/A |
| % Held by Insiders | 0.45% |
| % Held by Institutions | 97.36% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -294.74% |
| Operating Margin (ttm) | -228.63% |
| Gross Margin | -94.50% |
| EBITDA Margin | -228.10% |
Management Effectiveness
| Return on Assets (ttm) | -38.91% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 80.97M USD |
| Revenue Per Share (ttm) | 1.14 USD |
| Quarterly Revenue Growth (yoy) | 29.19% |
| Gross Profit (ttm) | -70419000 USD |
| EBITDA | -184688992 USD |
| Net Income Avi to Common (ttm) | -238647008 USD |
| Diluted EPS (ttm) | -6.24 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 162.34M USD |
| Total Cash Per Share (mrq) | 1.71 USD |
| Total Debt (mrq) | 513.22M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.625 |
| Book Value Per Share (mrq) | -3.779 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -190192992 USD |
| Levered Free Cash Flow (ttm) | -149338496 USD |
Profile of Esperion Therapeutics, Inc.
| Country | United Kingdom |
| State | MI |
| City | Ann Arbor |
| Address | 3891 Ranchero Drive |
| ZIP | 48108 |
| Phone | 734 887 3903 |
| Website | https://www.esperion.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 199 |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Q&A For Esperion Therapeutics, Inc. Stock
What is a current 0IIM.L stock price?
Esperion Therapeutics, Inc. 0IIM.L stock price today per share is 2.15 USD.
How to purchase Esperion Therapeutics, Inc. stock?
You can buy 0IIM.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Esperion Therapeutics, Inc.?
The stock symbol or ticker of Esperion Therapeutics, Inc. is 0IIM.L.
How many shares does Esperion Therapeutics, Inc. have in circulation?
The max supply of Esperion Therapeutics, Inc. shares is 324K.
What is Esperion Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Esperion Therapeutics, Inc. PE Ratio is now.
What was Esperion Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Esperion Therapeutics, Inc. EPS is -6.24 USD over the trailing 12 months.